RWE Solutions for Phase IV Studies and Surveillance

Real-World Evidence Solutions for Phase IV Studies and Post-Market Surveillance

Drive Impactful Outcomes with Verana Health's RWE for Phase IV Studies

Real-world evidence (RWE) is essential for understanding how treatments perform in real-world settings. Verana Health’s Phase IV Studies and Surveillance solutions leverage exclusive data from the American Academy of Ophthalmology and the American Urological Association to gain access to comprehensive, de-identified data that drives postmarketing insights for safer, more effective healthcare.

Meet with Verana Health

Exclusive, High-Quality Data for In-Depth Postmarketing Surveillance

Verana Health’s exclusive partnerships with the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) and the American Urological Association (AUA) Quality (AQUA)® Registry, allow us access to rich real-world data (RWD). Verana Health ingests and curates the data, then applies advanced artificial intelligence (AI) techniques to generate Qdata®—research-ready, fit-for-purpose datasets designed to drive business insights and inform research outcomes.

Qdata delivers key variables from structured and unstructured electronic health record (EHR) data, providing a unique view of treatment patterns, long-term outcomes, and real-world effectiveness across diverse patient populations. Our commitment to data quality, coupled with proprietary analytics, transforms RWD into invaluable resources for postmarketing safety studies, performance tracking, and safety signal detection.

Meet with Verana Health

Key Benefits of Phase IV & Surveillance Solution From Verana Health

  • Unmatched EHR-Derived Clinical Data
    Gain insights from more than 11 years of longitudinal data on 90 million de-identified patients from 20,000 contributing clinicians. Understand treatment effects and safety in real-world settings with datasets that include a variety of demographic, treatment, and outcome variables.
  • Fit-for-Purpose Evidence
    Verana Health’s high-quality data can support evidence generation for decision-making bodies, aiding in the development of supplementary labeling, expanded indications, or additional safety information. Provide timely data reflective of current clinical care  and enhance product value with comprehensive, real-world evidence. Learn more about FDA guidance on RWE.
  • Customized Analytics for Precision Insights
    From assessing long-term treatment outcomes to evaluating patient adherence, Verana Health provides tailored analytics that focus on your unique objectives. With tools to analyze treatment performance by patient type, you gain a precise understanding of how ophthalmology and urology therapies perform in various populations.

Why Choose Verana Health for Phase IV and Surveillance Solutions?

Verana Health’s commitment to excellence in RWD analytics and advanced AI, combined with exclusive data from our society partnerships, offers unparalleled support for life sciences companies aiming to monitor and enhance the safety and efficacy of treatments.

By choosing Verana Health for Phase IV and Surveillance solutions, you’re leveraging trusted, high-quality data for RWE generation, which can help inform decision-making  and advance patient outcomes.

Meet with the Verana Health Team or View a Demo

Schedule Now

Featured Content

Press

Verana Health Launches Real-World Evidence-Driven Solution for Clinical Trial Site Selection

June 2023
→
Blog

Empowering a Real-World Data-Driven Approach to Clinical Trial Site Selection

June 2023
→
Blog

Verana Health Marks Milestone with 2022 MIPS Submissions for IRIS Registry and Axon Registry

May 2023
→
VeranaHealth_Logo

Ready to Elevate Your Phase IV Studies with Verana Health?

Learn how Verana Health’s Phase IV and Surveillance solutions can support your postmarketing strategies. Let us help you drive impactful, evidence-based outcomes with insights drawn directly from the clinical frontlines. Contact us today.